89bio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/22
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022GlobeNewsWire • 11/05/22
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor ConferenceGlobeNewsWire • 10/13/22
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022GlobeNewsWire • 08/26/22
89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASHGlobeNewsWire • 08/18/22
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/22
89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 07/05/22
89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 06/29/22
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 06/28/22
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)GlobeNewsWire • 06/28/22
89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022GlobeNewsWire • 06/21/22
89bio Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/22
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/24/22
89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare ConferenceGlobeNewsWire • 02/09/22
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASHGlobeNewsWire • 01/24/22
89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen VolumeGlobeNewsWire • 11/14/21
89bio Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/11/21
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's The Liver Meeting 2021GlobeNewsWire • 10/25/21